**Question:** Anti-glaucoma drug that acts by increasing uveoscleral outflow is

A. Timolol
B. Latanoprost
C. Dorzolamide
D. Brimonidine

**Correct Answer:** D. Brimonidine

**Core Concept:**

Uveoscleral outflow is an alternative pathway for aqueous humor drainage in the eye, bypassing the conventional outflow pathway (the trabecular meshwork) which is the primary target of most anti-glaucoma medications. Inadequate uveoscleral outflow contributes to increased intraocular pressure (IOP) and is involved in the pathogenesis of glaucoma.

**Why the Correct Answer is Right:**

Brimonidine is a selective alpha-2 adrenergic receptor agonist, which works by increasing the activity of the alpha-2 receptor in the uveoscleral outflow pathway. Alpha-2 agonists stimulate the alpha-2 receptors on the trabecular meshwork, leading to relaxation of the smooth muscles and increased aqueous humor outflow. This results in a decrease in intraocular pressure (IOP) and helps in the treatment of glaucoma.

**Why Each Wrong Option is Incorrect:**

A. Timolol: Timolol is a beta-blocker that primarily inhibits beta-1 receptors in the heart and vasculature, which is why it is primarily used for cardiovascular conditions. It does not target alpha-2 receptors in the uveoscleral outflow pathway, so it is not an effective anti-glaucoma medication.

B. Latanoprost: Latanoprost is a prostaglandin analog that increases the outflow of aqueous humor through the conventional outflow pathway (trabecular meshwork) by stimulating prostaglandin F2 alpha receptor. It does not specifically target the uveoscleral outflow pathway, so it is not the correct answer.

C. Dorzolamide: Dorzolamide is a carbonic anhydrase inhibitor that works by suppressing the production of aqueous humor in the ciliary body. It reduces intraocular pressure (IOP) by decreasing the aqueous humor production, but it does not increase the outflow through the uveoscleral pathway, making it an incorrect answer for increasing uveoscleral outflow.

**Clinical Pearl:**

Understanding the different mechanisms of action for various anti-glaucoma medications is essential for choosing the appropriate treatment for patients with glaucoma or ocular hypertension. In addition to alpha-2 agonists like brimonidine, there are other classes of medications such as beta-blockers (Timolol), prostaglandin analogs (Latanoprost), and carbonic anhydrase inhibitors (Dorzolamide), which target different aspects of aqueous humor production and outflow. Choosing the correct medication based on the patient's specific condition and IOP goals is crucial for managing ocular hypertension and primary open-angle glaucoma.